# Aimmune Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aimmune-therapeutics

- Industry: Biotechnology
- Headquarters: Brisbane, US
- Website: www.aimmune.com
- Total disclosed funding: $97M
- Latest round: Series B (Jan 20, 2015)
- Investors on record: 7

## About

Aimmune Therapeutics Inc. is a biopharmaceutical company focused on developing innovative treatments for food allergies, primarily targeting peanut allergies with its oral immunotherapy product.Founded in 2011 in Brisbane, US, Aimmune Therapeutics develops therapies for food allergies. The company pioneered its flagship product, Palforzia, which was released after extensive clinical trials. Aimmune has undergone significant funding, including a TRADE SALE in February 2018 that raised USD 2,100.00 mn led by Nestle Health Science SA, bringing its total amount raised to USD 2,100.00 mn and current valuation to USD 2,600.00 mn. The company has completed 5 deals since inception. Jayson Dallas is the current CEO.Aimmune Therapeutics specializes in developing treatments for food allergies, with Palforzia as its primary product. This oral immunotherapy aims to desensitize individuals to peanuts, significantly decreasing the likelihood of allergic reactions. It is mainly targeted at children and adolescents aged 4 to 17 years but is also applicable to adults. Aimmune serves healthcare providers and families affected by food allergies, marketing its products primarily in the United States with plans for international expansion.In 2019, Aimmune Therapeutics reported an EBITDA of USD -247,349,000, primarily deriving revenue from sales of Palforzia. The company employs a direct-to-consumer approach along with partnerships with healthcare providers, facilitating patient access to its therapies through insurance reimbursement processes, which ensures accessibility while maintaining profitability.Aimmune Therapeutics plans to introduce new products and expand its market presence, particularly focusing on international markets such as Europe and Canada. The latest funding round, completed in February 2018, raised USD 175.00 mn which will support these initiatives. The company has a historical precedent of raising substantial funds, notably USD 160.00 mn during its IPO in August 2015, positioning it well for future growth.

## Funding rounds

- Series B, Jan 20, 2015, $80M — Aisling Capital, Adage Capital Management, Longitude Capital, Fidelity Investments, Palo Alto Investors, Foresite Capital, RA Capital Management
- Series A, Nov 21, 2013, $17M — Longitude Capital

## Investors

- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series A, Series B
- Aisling Capital (https://capitalatlas.ai/funds/aisling-capital) — Series B
- Adage Capital Management — Series B
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series B
- Palo Alto Investors (https://capitalatlas.ai/funds/palo-alto-investors) — Series B
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B